The efficacy and safety of twice-a-day Insulin degludec /insulin aspart compared with the traditional intensive treatment regimen of four times a day in newly diagnosed type 2 diabetes mellitus

The efficacy and safety of twice-a-day Insulin degludec /insulin aspart compared with the traditional intensive treatment regimen

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042914

Enrollment

Unknown

Registered

2021-01-31

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Insulin degludec/Insulin aspart group:Insulin degludec/Insulin aspart therapy

insulin detemir combined Insulin aspart group:insulin detemir combined Insulin aspart therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A total of 100 patients were enrolled according to the screening criteria of the project. The inclusion criteria were as follows: 1. Patients with type 2 diabetes were enrolled with (1) Blood glucose >= 11.1mmol/L at any time and had diabetes symptoms according to WHO criteria. (2) Fasting blood glucose (FPG) >= 7.0 mmol/L. (3) Oral glucose tolerance test (2HPG) >=11.1 mmol/L. 2. Aged between 18 and 65 years; 3. Duration of diabetes is 5 years; 4. HbA1C 9% or higher.

Exclusion criteria

Exclusion criteria: 1. Acute complications of diabetes, such as hyperosmolarity, diabetic ketoacidosis; 2. Complicated with lung, kidney, liver and other serious abnormal function; 3. Women who are lactating or pregnant; 4. People with allergies; 5. Mentally ill.

Design outcomes

Primary

Measure	Time frame
FBG (fasting blood-glucose);postprandial blood sugar;The incidences of hypoglycemia;	—

Secondary

Measure	Time frame
3 AM blood sugar;	—

Countries

China

Contacts

Public ContactYing Song

Xichang People's Hospital

773604617@qq.com+86 18981561711

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026